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experienced enormous advances from
which most have so far not been incorpo-
rated into standard medical practice (Da-
vis, 2008). One approach to fully exploit
the existing wealth of knowledge is to
implement a systematic strategy to eval-
uate the immune system. The potential
benefit of such an approach is that it
may lead to results that can be translated
into the rational development of diagnos-
tics and therapeutics (Hoos et al., 2011).
Two prerequisites for its application are
that (1) applied immune assays lead to
reproducible results (van der Burg et al.,
2011), and (2) sets of experimental results
will be reported and deposited in a way
that supports maximum use of data (Ja-
netzki et al., 2009; Sansone et al., 2012).
The task of establishing robust assays
has been shown to be particularly chal-
lenging for cellular assays. This has
led to multiple independent activities to
harmonize and standardize immune
assays (van der Burg et al., 2011;Maeckeret al., 2010; Roep et al., 2012). Experi-
ments conducted by more than 100 labs
showed that (1) a plethora of different
protocols exists, (2) results generated
across institutions vary greatly, (3)multiple
process steps contribute to test variation,
(4) many labs performing T cell assays do
not control critical process steps, and (5)
the majority of reports comprising results
from T cell assay experiments lack critical
information. At first these findings were
met with skepticism, given that they
seemed to contradict promising results
showing that cellular assays can consti-
tute robust tools to quantify antigen-
specific T cell responses. However, both
the optimistic and the pessimistic view
have validity. T cell assays can deliver
compelling performance in the hands of
skilled researchers. Nonetheless, pulling
data from heterogeneous groups of labs
demonstrates that controlling the perfor-
mance of cellular assays requires explicit
knowledgeof their critical protocol details.
Notably, publications lacking those criticalImmuprotocol details may be difficult to inter-
pret and to reproduce. Such reporting
issues have the potential to hamper prog-
ress in the field.
To provide a solution, the Minimal Infor-
mationabout TCell Assays (MIATA) project
was initiated in 2009 (Janetzki et al.,
2009) as a field-spanning initiative whose
main objective is to generate a broadly
acceptable framework for the reporting of
results from commonly used T cell assays,
which is envisioned to be expandable to
new, complex assays (Sharma et al.,
2011; for a full list of MIATA contributors,
see http://www.miataproject.org/index.
php?option=com_content&view=article&
id=4&Itemid=6).
The generated MIATA guidelines pre-
sented here are the outcome of one of
the most intensive community-wide
vetting processes in the field of immu-
nology so far (Britten et al., 2011). This
process and all its steps are transparently
displayed at the project’s website (www.
miataproject.org). Importantly, MIATA isnity 37, July 27, 2012 ª2012 Elsevier Inc. 1
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Letternot about implementing standardization
rules on how to perform a T cell assay
nor does the project promote any specific
reagents or protocols. MIATA offers
minimum criteria for consistent reporting
of T cell assay results to increase data
interpretability and experimental repro-
ducibility across the scientific community.
Consequently, the current version of
MIATA is a testimonial to the freedom
and transparency of research and proves
the ability of the research community to
form consensus on critical variables
affecting the quality of their work.
Laboratories performing immunological
monitoring come in different flavors. On
one hand, there are research labs that
apply immune assays in a flexible way to
conduct high-quality research. On the
other hand, there are specialized core
labs with the main focus on the tightly
controlled performance of a selected
portfolio of immune assays. The MIATA
community acknowledges that both cate-
gories of labs are crucial as they harbor
complementary expertise needed to
achieve progress in research and devel-
opment and that a reporting framework
does not discredit any data set that was
not generated in a certified lab using a fully
standardized or validated assay.
The MIATA guidelines are divided into
modules and submodules for easy refer-
encing (Table S1). The modules address
critical information about:
1. the sample,
2. the assay,
3. the acquisition strategy,
4. the (interpretation of) raw data, and
5. the laboratory environment.
The MIATA website provides the guide-
lines as well as sample reports for the2 Immunity 37, July 27, 2012 ª2012 Elsevierfollowing assays: intracellular cytokine
staining, HLA-peptide multimer staining,
and Elispot. It further lists supplementary
information including relevant publica-
tions and definitions.
Adherence to MIATA guidelines is ex-
pected to enhance consistency of data
reporting across laboratories and in-
crease data reproducibility. As such, it is
recommended to be used broadly within
the community. We propose that adher-
ence to MIATA is optional. One envi-
sioned concept to implement MIATA is
that investigators submitting a research
article may choose to indicate whether
their article adheres to MIATA. This
can be accompanied by the executed
checklist available from the website.
Journals may additionally confirm via
peer review that all five MIATA modules
were sufficiently addressed, leading to
an official statement on MIATA compli-
ance in the article. Such a statement will
eventually be regarded as a ‘‘label of
honor’’ and a quality measure for the pub-
lished work. Depending on the adoption
rate in the scientific community, reporting
using MIATA might become a routine
practice that was not enforced from
top down but achieved in a bottom-up
approach.
MIATA’s promise is to offer more
consistent and transparent reporting of
T cell experiments in scientific publica-
tions making it easier to interpret and
reproduce published methods and data
sets. In addition, broad implementation
ofMIATAmight foster a stepwise increase
of the quality of applied immune assays
due to increased awareness of the critical
components impacting on test perfor-
mance. Accomplishing this mission
requires commitment from each member
of the immune monitoring communityInc.and support of journals to encourage but
not force authors to report according to
MIATA. The large number of experts
from different fields of immunology that
actively contributed to mature the project
is an indication of the high interest in such
guidelines. MIATA is ready for embrace-
ment by the immunology community at
large.
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